One-Pot Copper(I)-Catalyzed Ligand/Base-Free Tandem Cyclooxidative Synthesis of Quinazolinones

Kapil Upadhyaya,[†] Ravi Kumar Thakur,[†] Sanjeev K. Shukla,[‡] and Rama Pati Tripathi^{*,†}

[†]Medicinal and Process Chemistry Division, [‡]Sophisticated Analytical Instrument Facility, CSIR-Central Drug Research Institute (CSIR-CDRI), Sector 10, Jankipuram Extension, Sitapur Road, Lucknow-226031, India

Supporting Information



ABSTRACT: A novel and efficient Cu(I)-catalyzed ligand- and base-free multipathway domino strategy has been developed for the synthesis of 2-substituted quinazolinones. The reaction utilizes 2-bromobenzamide and multiform substrates such as aldehydes, alcohols, and methyl arenes for a one-pot protocol, whereas $TMSN_3$ is used as a nitrogen source. A wide range of substrate scope, functional group tolerance, and operational simplicity are synthetically useful features.

INTRODUCTION

Quinazolin-4-(3*H*)-one represents a class of annulated sixmembered nitrogen heterocycles (azaheterocycles) and a core structural component in a variety of natural products and biologically active compounds. Because of their ubiquitous nature and importance as a pharmacophore in drug candidates, they are assigned as privileged structures.¹ They are endowed with numerous pharmacological and biological activities such as anticancer,² antimalarial,³ antihypertensive,⁴ anti-inflammatory,⁵ and antituberculosis activities.⁶ In view of their remarkable significance, enormous efforts have been devoted toward efficient and convenient strategies for the construction of the quinazoline skeleton, especially 2-substituted quinazolines, as summarized in Figure 1.

Conventionally, synthesis of quinazolinone involves typical methodologies using acid/base-promoted condensation reaction of carboxylic acid derivatives with 2-aminobenzoic acid or its derivatives⁷ and cascade reaction of aldehydes with oaminobenzamides involving condensation, followed by oxidation of the aminal intermediate.⁸ However, these protocols suffer from certain disadvantages such as multistep synthesis, use of coupling agents/bases, use of ligand or additives, harsh reaction conditions, low yields, stoichiometric or large excess amounts of toxic oxidants, and the use of highly reactive 2aminobenzamide. Another drawback associated with these methodologies is the use of aldehyde, which is relatively unstable and synthesized from readily available alcohols via oxidation with different agents. Guo et al.9 have reported an efficient synthesis of quinazolinone from 2-bromobenzamide and aqueous ammonia as a source of nitrogen. Moreover, while holding merit, the strategy suffers from drawbacks such as the use of the excess of ammonia as well as ligand during the reaction. Apart from these, other methodologies have also been used involving the coupling of 2-halobenzoic acid or its



Figure 1. Methods for the synthesis of quinazolin-4-(3H)-one.

derivatives with ammonia sources which include benzylamines,¹⁰ amidines,¹¹ amino acids,¹² and amides,¹³ while all these approaches are efficient but suffered from drawbacks such as a use of the stoichiometric amounts of bases, which lead to the generation of salt wastes. Alternatively, an interesting palladium-catalyzed oxidative CO insertion reacting with 2aminobenzamide has been reported by Wu and co-workers.¹⁴ Recently, condensation of 2-aminobenzamide with aryl methyl ketones¹⁵ and keto alkynes¹⁶ was reported. During recent years,

 Received:
 March 21, 2016

 Published:
 May 25, 2016

Table 1. Optimizing Reaction Parameters for the Condensation of 2-Bromobenzamides with Aldehyde⁴



	1a	2a		3aa 💛		
S. no.	azide equivalent	base	catalyst	solvent	<i>T</i> (°C)	yield ^b (%)
1	TMSN ₃ (2 equiv)		CuCl	DMSO	80	66
2	TMSN ₃ (2 equiv)		$Cu(OAc)_2$	DMSO	80	72
3	TMSN ₃ (2 equiv)		Cu ₂ O	DMSO	80	60
4	TMSN ₃ (2 equiv)		$Cu(OTf)_2$	DMSO	80	65
5	TMSN ₃ (2 equiv)		CuI	DMSO	80	88
6	TMSN ₃ (2 equiv)		CuBr	DMSO	80	76
7	TMSN ₃ (2 equiv)		FeCl ₃	DMSO	80	NR
8	TMSN ₃ (1.0 equiv)		CuI	DMSO	80	60
9	TMSN ₃ (3 equiv)		CuI	DMSO	80	87
10	NaN ₃ (2.0 equiv)		CuI	DMSO	80	20
11	TMSN ₃ (2 equiv)	K ₂ CO ₃	CuI	DMSO	80	42
12	TMSN ₃ (2 equiv)	Cs ₂ CO ₃	CuI	DMSO	80	48
13	TMSN ₃ (2.0 equiv)		CuI	DMF	80	75
14	TMSN ₃ (2.0 equiv)		CuI	PhCl	80	64
15	$TMSN_3$ (2.0 equiv)		CuI	PEG-400	80	74
16	$TMSN_3$ (2.0 equiv)		CuI	dioxane	80	62
17	$TMSN_3$ (2.0 equiv)		CuI	ⁱ PrOH	80	68
18	TMSN ₃ (2.0 equiv)		CuI	DMSO	100	77
19	TMSN ₃ (2.0 equiv)		CuI	DMSO	70	71
20^{c}	TMSN ₃ (2.0 equiv)		CuI	DMSO	80	85
21 ^d	TMSN ₃ (2.0 equiv)		CuI	DMSO	80	69

^{*a*}Unless otherwise noted, the reactions were carried out with 1a (0.5 mmol), 2a (0.6 mmol), catalyst (0.05 mmol), and solvent (1.5 mL) at 80 °C in a sealed tube under an air atmosphere for 24 h. ^{*b*}Isolated yield of 3aa. ^{*c*}20 mol % of catalyst used. ^{*d*}5 mol % of catalyst used.

benzyl alcohols have been used for the synthesis of quinazolinones using Ir,¹⁷ Pt,¹⁸ and Pd¹⁹ as expensive and heavy metal catalysts for dehydrogenative oxidative cyclization, whereas a report on the use of methyl arenes or heteroarenes for the synthesis of quinazolinone is rare.²⁰ Considering all of these facts, we have next focused on the designing of a cascade reaction which uses aldehyde, alcohols, and methyl arenes to access quinazolinones. Herein, we report the use of aldehyde, alcohol, and methyl arenes/heteroarenes as coupling partners, which are cost-effective and easily available. Furthermore, the protocol is free from the use of ligand and base and uses TMSN₃ as nitrogen source and air/TBHP as oxidant.

RESULTS AND DISCUSSION

Taking into account the use of trimethylsilyl azide $(TMSN_3)$ as ammonia equivalent in cross-coupling reactions to afford the corresponding primary amine as the sole product,²¹ we initiated our investigation on a model reaction of 2-bromobenzamide (1a), benzaldehyde (2a), and TMSN₃ to optimize various reaction parameters as represented in Table 1.

Subsequent screening of the different copper salts and FeCl₃ with DMSO as a solvent at 80 °C under an air atmosphere was carried out (Table 1, entries 1–7). Among all the metal salts used, CuI exhibited relatively higher catalytic activity, whereas no product was formed with FeCl₃. The amount of TMSN₃ used was also investigated. As evident from the results, the transformation was affected when the TMSN₃ was reduced from 2 equiv to 1 equiv, which resulted in a relatively lower yield of **3aa** (Table 1, entry 8), whereas no appreciable change was observed when loading of TMSN₃ was increased to 3 equiv

(Table 1, entry 9). However, changing the azide from TMSN₃ to NaN_3 resulted in a poor yield of **3aa** (Table 1, entry 10). Addition of base proved to be detrimental to the reaction, as seen from the results, while the use of K₂CO₃ afforded only 42% of desired product, whereas Cs₂CO₃ did not result in any significant improvement in the yield of the product (Table 1, entries 11 and 12). Screening of solvents revealed that DMSO was the best solvent among the solvents (Table 1, entries 13-17). It was also observed that green solvent such as PEG-400 also afforded a good yield of the product. The effect of temperature on product yield was also monitored, and it was found out that increasing or decreasing the reaction temperature from 80 °C to 100 °C and 70 °C resulted in relatively less yield, i.e., 77% and 71%, respectively (Table 1, entries 18 and 19). No appreciable change in the yield was observed by increasing the catalyst loading from 10% to 20%. However, a decrease in the catalyst loading to 5% resulted in only 69% yield of the desired product (Table 1, entries 20 and 21).

Under the optimum reaction conditions (Table 1, entry 5), the scope and generality of this CuI-catalyzed domino reaction affording 2-substituted quinazolinones were subsequently investigated (Scheme 1).

The reactions with aryl-substituted aldehydes bearing electron-donating or electron-withdrawing groups proceeded smoothly to provide the desired products 3aa-1 in 64-89% yields. It is noteworthy to mention that fused aryl (e.g., 3am) and heteroaryl (e.g., 3an-aq) aldehydes were also well tolerated in this reaction, producing the corresponding products in good yields. To our delight, both alkenyl- (e.g., 3ar), benzyl- (e.g., 3au), and alkyl-substituted aldehydes (e.g.,

Article

Scheme 1. Scope of the Reaction for Synthesis of Various Quinazolin-4(3H)-ones from Aldehydes^a



^{*a*}Reaction conditions: 1a (0.5 mmol), aldehyde 2a-v (0.6 mmol), TMSN₃ (1.0 mmol), CuI (0.05 mmol), DMSO (1.5 mL), 80 °C, air, 24 h. The yields below the structure are isolated yields. ^{*b*}Reaction run for 48 h. ^{*c*}0.75 mmol of aldehyde used. ^{*d*}2 mL of formaldehyde used.

3as-t) were also well tolerated during this transformation to generate the corresponding products in good to moderate yields. A series of differently substituted 2-bromobenzamides such as methyl and methoxy were also successfully used in this tandem reaction to afford 2-substituted quinazolinones (3ba-cb) in yields ranging from 62% to 84%.

After the successful synthesis of 2-substituted quinazolinones from aldehydes, attempts to extend this methodology to alcohols and methyl arenes as substrates were then investigated. Encouraged by the previous reports of the oxidant's use in domino dual oxidative C-N coupling reactions,²⁰ a series of oxidants were additionally screened for the above-optimized reaction condition for the synthesis of quinazolinones as shown in Table 2. Among the various oxidants (TBHP, DTBP, DDQ, and $K_2S_2O_8$) examined, we observed that 2 equiv of TBHP proved to be the best yielding oxidant to access 2-substituted quinazolinone using alcohol instead of aldehyde in the threecomponent reaction (Table 2, entries 1-4). While DTBP yielded 71% of the product, the other two oxidants DDQ and $K_2S_2O_8$ proved to be inefficient. With 2 equiv of TBHP in the case of methyl arenes, the yield of the product 3aa was only 60%, but when TBHP was increased to 3 equiv, the yield was improved to 71%. Any further increase in the amount of TBHP (4.0 equiv) reduced the yield to 63% (Table 2, entries 5–7).

Table 2. Optimization of the Reaction Conditions for the Synthesis of 2-Substituted Quinazolin-4(3H)-one Using Alcohols and Methyl Arenes^a

O NH ₂ +	PhCH ₂ OH	or PhCH ₃	2 eq. TMSN ₃ oxidant <u>10 mol% Cul</u> DMSO, air,	
1a	4a	6a	80 °C	3aa
S. no.	substrate		oxidant ^c	yield ^b (%)
1	4a	TBH	ΙP	84
2	4a	DTE	3P	71
3	4a	DDC	2	0
4	4a	K_2S_2	O ₈	trace
5	6a	TBH	ΗP	60
6	6a	TBH	IP (3 equiv)	71
7	6a	TBH	IP (4 equiv)	63

^{*a*}Unless otherwise noted, the reactions were carried out with 1a (0.5 mmol), 4a (0.6 mmol), 6a (2 mL) catalyst (0.05 mmol), and solvent (1.5 mL) at 80 $^{\circ}$ C in a sealed tube under an air atmosphere for 24 h. ^{*b*}Isolated yield of 3aa. ^{*c*}0.8 mmol of oxidant was used.

With the optimized reaction conditions for best yield, we explored the scope of the oxidative tandem reaction to access a





^aReaction conditions: **1a** (0.5 mmol), alcohol **5a-o** (0.6 mmol), TMSN₃ (1.0 mmol), TBHP (1.0 mmol, 70% aqueous solution), CuI (0.05 mmol), DMSO (1.5 mL), 80 °C, air, 24 h. The yields below the structure are isolated yields. ^b0.75 mmol of alcohol used.

Scheme 3. Scope of the Reaction for Synthesis of Various Quinazolin-4(3H)-ones from Methyl Arenes^a



"Reaction conditions: 1a (0.5 mmol), methyl arenes 6a-g (2 mL), TMSN₃ (1.0 mmol), TBHP (1.5 mmol, 70% aqueous solution), CuI (0.05 mmol), DMSO (1.5 mL), 80 °C, air, 24 h.

series of 2-substituted quinazolinones derived from alcohol or methyl arenes, as depicted in Schemes 2 and 3.

Benzyl alcohols bearing electron-donating and electronwithdrawing groups readily reacted, affording 2-substituted quinazolinones in good to excellent yields (Scheme 2). It is worthy to note that chloro and bromo substituents survived during the reaction (3ah-i). Naphthyl alcohol, cinnamyl alcohol, and heteroaryl alcohols furnished the desired products in good to excellent yields. Interestingly, alkyl alcohols reacted well under the standard conditions to provide 2-substituted Scheme 4. Control Experiments and Effect of Radical Inhibitor



quinazolinones in satisfactory yields (5al-m). Differently substituted 2-bromobenzamides also afforded the good yield of the respective products.

Under the optimized reaction conditions, when toluene reacted with 2-bromobenzamide, it afforded a good yield of the desired product **3aa** (Scheme 3). With electron-donating substituents such as 4-methylanisole, a drop in yield was observed (**3ab**). Reaction with substrate having more than one benzylic carbon, i.e., mesitylene, proceeded sluggishly, providing a moderate yield of quinazolinone (**7ac**). 2-Methyl thiophene also proved to be a good substrate for this transformation (**3ar**) in a moderate yield. The reaction of *ortho-, para-,* and *meta-xylenes* with 2-bromobenzamide afforded good to moderate yields of the respective quinazolinones without affecting their other methyl group (**7ae**-**7ag**).

To gain an insight into the cyclooxidative mechanism of quinazolinone formation from *ortho*-halobenzamides during this study, a series of control experiments were carried out. Under a N_2 atmosphere, the reaction of 2-bromobenzamide with benzaldehyde using TMSN₃ and CuI as catalyst at 80 °C yielded mainly the dihydroquinazolinone intermediate **9** (78%) along with the desired **3aa** (5%) (Scheme 4, eq 1). The aerial oxidation of **9** with or without CuI resulted in 90% and 39% yield of the desired product **3aa**, respectively (Scheme 4, eq 2). This indicates that the CuI and the air are essential for the transformation. However, reaction of 2-bromobenzamide with TMSN₃ using CuI as a catalyst at 80 °C under an air atmosphere afforded 2-aminobenzamide (**8**) in 4% yield only (Scheme 4, eq 3). This trace amount of reductive product could be explained due to the lack of proton source in this reductive cleavage.^{22a}

Inhibition of reaction was observed when TEMPO (2,2,6,6-tetramethylpipridine-*N*-oxyl), a radical inhibitor, was added to the reaction system, indicating the radical process nature (Scheme 4, eq 4). This result shows that the oxidation of benzyl alcohol to benzaldehyde, which is needed in order for the reaction to proceed, is a radical process during the reaction.





The same negative effect was also observed when methyl arene was used as a substrate for the synthesis of quinazolinone (Scheme 4, eq 5). In addition, it was found that the amino group played a crucial role in intermolecular C–N bond formation (Scheme 4, eq 6). According to a literature report, a *tert*-butoxy intermediate was involved in C–N bond formation.^{22b} Considering this fact, we speculated that, during the reaction, *tert*-butyl benzyl ether was generated, which underwent intermolecular amination of **1a** to give **11**. According to our expection, 51% of the desired product was obtained when **1a** was reacted with **10a** under standard reaction conditions (Scheme 4, eq 7).

In accordance with the above results and the literature precedents, a possible mechanism is proposed as shown in Scheme 5. Initially, CuI undergoes oxidative addition with substrate 1a to give complex A, which undergoes subsequent treatment with TMSN₃ to give complex **B**, followed by coppercatalyzed denitrogenative reaction in the presence of a trace amount of H_2O present in DMSO to provide complex C. The latter readily gets reduced into 2-aminobenzamide (8) with the aid of moisture present in DMSO during the reaction to complete the catalytic cycle. On the other hand, benzyl alcohol is oxidized to benzaldehyde via a radical pathway with TBHP. The reaction of benzaldehyde and 2-aminobenzamide afforded an imine (12). CuI-assisted decomposition of TBHP leads to formation of tert-butoxyl and tert-butylperoxy radicals. tert-Butoxyl radical abstracts a H· radical from toluene to give a benzyl radical. Subsequent coupling of the kinetically stable tertbutylperoxy radical^{22c-f} and benzyl radical (PhCH₂· and ^tOOBu·) generated intermediate 10b (Path B). This intermediate undergoes intermolecular amination by reacting with 8, which gets oxidized to imine (12). Moreover, intermediate 11 formation can be explained by intermolecular C-N bond

formation by *tert*-butylbenzyl ether (10a), which is generated by the coupling of benzyl radical and *tert*-butoxy radical (Path A). Subsequently, the imine generated underwent intramolecular cyclization, followed by oxidation, to furnish the desired product **3aa**.

CONCLUSION

In summary, we have designed and developed a convenient, highly efficient, operationally simple, ligand- and base-free onepot protocol for the synthesis of 2-substituted quinazolinones from 2-bromobenzamide. It provides a diverse synthetic approach, utilizing inexpensive and readily available multiform substrates, aldehydes, alcohols, and methyl arenes, and uses TMSN₃ as nitrogen source via a multipathway coupled selfsequenced domino reaction involving oxidative addition, reductive amination, an intermolecular oxidative nitrogenation of a benzylic C(sp³)-H bond, intramolecular cyclization, and oxidative dehydrogenation assembled in a single reactor to afford the desired product. Particularly noteworthy is that the broad substrate scope, high yield, and functional group compatibility are significant practical advantages. Even though our strategy augurs an interesting synthetic methodology, further exploring the novel synthetic approach toward the synthesis of other N-containing heterocycles and understanding a detailed mechanism is underway in our laboratory.

EXPERIMENTAL SECTION

General Information. Commercially available reagent grade chemicals were used as received. All reactions were monitored by TLC on an E. Merck Kieselgel 60 F254, with detection by UV light, spraying Dragendorff's solution. Column chromatography was performed on silica gel (60-120 and 230-400 mesh size). IR spectra were recorded as thin films or in KBr solution using an FTIR (4000–450 cm⁻¹) spectrophotometer. ¹H and ¹³C NMR spectra were

The Journal of Organic Chemistry

recorded on 400, 300, 100, and 75 MHz spectrophotometers, respectively, in CDCl₃ and DMSO- d_6 . Chemical shift values are reported in ppm relative to TMS (tetramethylsilane) as the internal reference, unless otherwise stated; s (singlet), d (doublet), t (triplet), dd (doublet of doublets), m (multiplet); J in hertz. The LC-ESI-MS were recorded on a triple-quadrupole (TQD) mass spectrometer, and HRMS spectra were performed using a mass spectrometer Q-TOF. The 10 μ L samples (dissolved in solvent such as methanol/ acetonitrile/water) were introduced into the ESI source through an autosampler. The mobile phase 90:10 MeOH/CH₃CN:H₂O flowed at the rate of 250 μ L/min by an MS pump. Ion spray voltage was set at 5.3 kV and the capillary voltage at 34 V. The MS scan was run up to 2.5 min, and the spectra's printouts are averages of over 10 scans at peak top in TIC.

General Procedure for Preparation of 2-Substituted Quinazolin-4(3H)-ones Using Aldehydes. To a mixture of 2bromobenzamide 1a (0.10 g, 0.5 mmol), aldehyde 2a-v (0.6 mmol), and CuI (0.01 g, 0.05 mmol) in DMSO (1.5 mL) was added TMSN₃ (0.13 mL, 1.0 mmol) in a tube under an air atmosphere. After that, the tube was sealed, and the reaction mixture was heated at 80 °C for 24 h. After completion of the reaction, water (20 mL) was added to it. A saturated aq. Na₂S₂O₃ solution was added until the disappearance of brown color, and the reaction mixture was extracted with ethyl acetate. The combined organic layer was dried on anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the crude product was purified by column (SiO₂, 60-120) chromatography using 15-20% EtOAc:hexane as eluent to get pure quinazolinone products. Most of the compounds were purified without any column chromatography, where ethyl acetate was added to the crude product and the resulting suspension was filtered. It was washed with ethyl acetate 2-3 times to get a pure compound. Again, the filtrate was concentrated, and this process was repeated 2-3 times to get a good yield of the products.

General Procedure for the Synthesis of 2-Substituted Quinazolin-4(3H)-ones Using Alcohol. To a mixture of 2bromobenzamide 1a (0.10 g, 0.5 mmol), alcohol 4a–o (0.6 mmol), and CuI (0.01 g, 0.05 mmol) in DMSO (1.5 mL) were added TMSN₃ (0.13 mL, 1.0 mmol) and TBHP (0.1 mL, 1.0 mmol, 70% aqueous solution) in a tube under an air atmosphere. After that, the tube was sealed, and the reaction mixture was heated at 80 °C for 24 h. After completion of the reaction, the same procedure was followed as reported above.

General Procedure for the Synthesis of 2-Substituted Quinazolin-4(3H)-ones Using Methyl Arenes. To a mixture of 2-bromobenzamide 1a (0.10 g, 0.5 mmol), methyl arenes 6a-g (2 mL), and CuI (0.01 g, 0.05 mmol) in DMSO (1.5 mL) were added TMSN₃ (0.13 mL, 1.0 mmol) and TBHP (0.14 mL, 1.0 mmol, 70% aqueous solution) in a tube under an air atmosphere. After that, the tube was sealed, and the reaction mixture was heated at 80 °C for 24 h. After completion of the reaction, the same procedure was followed as reported above, and the crude product was purified by column (SiO₂, 230-400) chromatography using 15–20% EtOAc:hexane as eluent to get pure quinazolinone products.

2-Phenylquinazolin-4(3H)-one (**3aa**).¹⁰ White solid; Yield: 88% (97 mg); mp 230–232 °C (lit. 232–235 °C); IR (KBr) cm⁻¹: 3403, 3019, 1670, 1403, 1069; ¹H NMR (400 MHz, DMSO- d_6): δ 12.54 (s, 1H), 8.20–8.15 (m, 3H), 7.86–7.82 (m, 1H), 7.76 (d, J = 8.00 Hz, 1H), 7.62–7.51 (m, 4H); ¹³C NMR (100 MHz, DMSO- d_6 + CDCl₃): δ 162.7, 152.6, 149.2, 134.8, 133.1, 131.6, 128.9, 128.1, 127.9, 126.8, 121.4. HRMS calcd for C₁₄H₁₀N₂O [M + H⁺] 223.0866, found 223.0862.

2-(4-Methoxyphenyl)quinazolin-4(3H)-one (**3ab**).²⁰ White solid; Yield: 89% (112 mg); mp 242–247 °C (lit. 247–249 °C); IR (KBr) cm⁻¹: 3400, 3019, 1676, 1403, 1385, 1069, 758 cm⁻¹; ¹H NMR (400 MHz, DMSO- d_6): δ 12.41 (br.s, 1H), 8.21–8.18 (dd, J_1 = 6.99 Hz, J_2 = 2.01 Hz, 2H), 8.14–8.12 (dd, J_1 = 7.94 Hz, J_2 = 1.15 Hz, 1H), 7.84–7.79 (m, 1H), 7.71 (d, J = 7.66 Hz, 1H), 7.50–7.46 (m, 1H), 7.10 (d, J = 9.00 Hz, 2H), 3.85 (s, 3H); ¹³C NMR (100 MHz, DMSO- d_6): δ 162.7, 162.3, 152.3, 149.4, 135.0, 129.9, 127.7, 126.5, 126.2, 125.2, 121.1, 114.4, 55.9. HRMS calcd for $C_{15}H_{12}N_2O_2 \ [M+H^+]$ 253.0972, found 253.0965.

2-(2-Methoxyphenyl)quinazolin-4(3H)-one (**3ac**).²³ White solid; Yield: 83% (105 mg); mp 200–202 °C (lit. 198–202 °C); IR (KBr) cm⁻¹: 3406, 1676, 1603, 1402, 1217, 1070; ¹H NMR (400 MHz, DMSO- d_6): δ 12.11 (br.s, 1H), 8.16–8.14 (dd, J_1 = 7.89 Hz, J_2 = 1.20 Hz, 1H), 7.85–7.81 (m, 1H), 7.72–7.70 (dd, J_1 = 7.56 Hz, J_2 = 1.82 Hz, 1H), 7.56–7.51 (m, 2H), 7.20 (d, J = 8.23 Hz, 1H), 7.11–7.07 (m, 1H), 3.86 (s, 3H); ¹³C NMR (100 MHz, DMSO- d_6): δ 161.6, 157.6, 152.8, 149.5, 134.8, 132.6, 130.9, 127.8, 127.0, 126.2, 123.0, 121.4, 120.9, 112.3, 56.2. HRMS calcd for C₁₅H₁₂N₂O₂ [M + H⁺] 253.0972, found 253.0972.

2-(3-Methoxyphenyl)quinazolin-4(3H)-one (**3ad**).¹⁷ White solid; Yield 82% (103 mg); mp 180–182 °C (lit. 181–183 °C); IR (KBr) cm⁻¹: 3019, 1672, 1607, 1403, 1070; ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.53 (s, 1H), 8.17 (d, *J* = 7.25 Hz, 1H), 7.87–7.82 (m, 1H), 7.80 (d, *J* = 7.79 Hz, 1H), 7.76–7.74 (m, 2H), 7.55–7.51 (t, *J* = 7.16 Hz, 1H), 7.48–7.44 (t, *J* = 7.97 Hz, 1H), 7.17–7.14 (dd, *J*₁ = 8.16 Hz, *J*₂ = 1.99 Hz, 1H), 3.87 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆): δ 162.8, 159.8, 152.6, 148.9, 135.2, 134.4, 130.3, 127.8, 127.2, 126.3, 121.3, 120.5, 118.0, 113.0, 55.8. HRMS calcd for $C_{15}H_{12}N_2O_2$ [M + H⁺] 253.0972, found 253.0964.

2-(4-(*lsopropyl*)*phenyl*)*quinazolin-4*(*3H*)-*one* (*3ae*).²⁴ White solid; Yield 79% (104 mg); mp 271–273 °C (lit. 270–273 °C); IR (KBr) cm⁻¹: 3019, 1672, 1403, 1215, 1069; ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.48 (br.s, 1H), 8.16–8.12 (m, 3H), 7.85–7.81 (m, 1H), 7.74 (d, *J* = 7.66 Hz, 1H), 7.53–7.49 (m, 1H), 7.43 (d, *J* = 8.23 Hz, 2H), 3.02–2.95 (m, 1H), 1.25 (s, 3H), 1.24 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆): δ 162.7, 152.7, 152.5, 149.3, 135.0, 130.7, 128.2, 127.9, 127.0, 126.8, 126.3, 121.3, 33.8, 24.0 (2C). HRMS calcd for C₁₇H₁₆N₂O [M + H⁺] 265.1335, found 265.1334.

2-(3,4,5-Trimethoxyphenyl)quinazolin-4(3H)-one (**3af**).²⁵ White solid; Yield 74% (115 mg); mp 257–260 °C (lit. 258–260 °C); IR (KBr) cm⁻¹: 3401, 3019, 1654, 1403, 1156; ¹H NMR (400 MHz, DMSO- d_6): δ 12.51 (s, 1H), 8.16 (d, *J* = 7.64 Hz, 1H), 7.85–7.82 (t, *J* = 7.25 Hz, 1H), 7.76 (d, *J* = 8.03 Hz, 1H), 7.57 (s, 2H), 7.53–7.50 (t, *J* = 7.44 Hz, 1H), 3.91 (s, 6H), 3.75 (s, 3H); ¹³C NMR (100 MHz, DMSO- d_6): δ 162.5, 158.0, 156.9, 153.8, 145.4, 139.8, 132.8, 132.6, 131.7, 131.0, 126.0, 110.4, 65.3, 61.3. HRMS calcd for C₁₇H₁₆N₂O₄ [M + H⁺] 313.1183, found 313.1175

2-(4-Fluorophenyl)quinazolin-4(3H)-one (**3ag**).²⁰ White solid; Yield: 78% (93 mg); mp 284–286 °C (lit. 284–287 °C); IR (KBr) cm⁻¹: 3402, 3019, 2400, 1659, 1403, 1215, 1069; ¹H NMR (400 MHz, DMSO- d_6): δ 12.57 (br.s, 1H), 8.27–8.24 (m, 2H), 8.17–8.14 (dd, J_1 = 7.89 Hz, J_2 = 1.10 Hz, 1H), 7.86–7.82 (m, 1H), 7.75 (d, J = 7.94 Hz, 1H), 7.55–7.51 (m, 1H), 7.42–7.37 (m, 2H); ¹³C NMR (100 MHz, DMSO- d_6): δ 165.7 (d, J_{C-F} = 251.34 Hz), 162.7, 151.9, 149.0, 135.1, 130.8 (d, J_{C-F} = 9.38 Hz), 129.6, 127.9, 127.1, 126.3, 121.2, 116.2 (d, J_{C-F} = 21.96 Hz). HRMS calcd for C₁₄H₉FN₂O [M + H⁺] 241.0772, found 241.0780

2-(4-Chlorophenyl)quinazolin-4(3H)-one (**3a**h).²⁰ White solid; Yield: 76% (97 mg); mp > 300 °C (lit. 298–300 °C); IR (KBr) cm⁻¹: 3408, 3308, 3021, 2401, 1672, 1606, 1480, 1409, 1154, 1093; ¹H NMR (400 MHz, DMSO- d_6): δ 12.59 (br.s, 1H), 8.21 (d, *J* = 8.30 Hz, 2H), 8.17 (d, *J* = 7.72 Hz, 1H), 7.86–7.83 (t, *J* = 7.34 Hz, 1H), 7.75 (d, *J* = 8.11 Hz, 1H), 7.64 (d, *J* = 8.40 Hz, 2H), 7.55–7.52 (t, *J* = 7.34 Hz, 1H); ¹³C NMR (100 MHz, DMSO- d_6): δ 162.6, 151.8, 149.0, 136.7, 135.1, 132.0, 130.0 (2C), 129.1 (2C), 127.9, 127.2, 126.3, 121.4; HRMS calcd for C₁₄H₉ClN₂O [M + H⁺] 257.0476, found 257.0478.

2-(4-Bromophenyl)quinazolin-4(3H)-one (**3ai**).^{8d} White solid; Yield: 69% (103 mg); mp 292–294 °C (lit. 292–295 °C); IR (KBr) cm⁻¹: 3412, 3019, 1650, 1403, 1110, 1065; ¹H NMR (400 MHz, DMSO- d_6): δ 12.60 (br.s, 1H), 8.17–8.11 (m, 3H), 7.87–7.83 (m, 1H), 7.78–7.74 (m, 3H), 7.56–7.52 (m, 1H); ¹³C NMR (100 MHz, DMSO- d_6): δ 162.6, 151.9, 149.0, 135.1, 132.3, 132.1, 130.2, 127.9, 127.3, 126.3, 125.7, 121.4. HRMS calcd for C₁₄H₉BrN₂O [M + H⁺] 300.9971, found 300.9971.

2-(4-Nitrophenyl)quinazolin-4(3H)-one (3aj).²⁶ Yellow solid; Yield: 64% (85 mg); mp > 300 °C (lit. > 300 °C); IR (KBr) cm⁻¹:

3402, 3019, 2399, 1643, 1522, 1403, 1069; ¹H NMR (400 MHz, DMSO- d_6): δ 12.82 (br.s, 1H), 8.44–8.37 (m, 4H), 8.20–8.17 (dd, J_1 = 7.85 Hz, J_2 = 1.15 Hz, 1H), 7.90–7.86 (m, 1H), 7.81–7.79 (d, J = 8.04 Hz, 1H), 7.60–7.56 (m, 1H); ¹³C NMR (100 MHz, DMSO- d_6): δ 162.6, 151.3, 149.4, 148.7, 139.0, 135.3, 129.7 (2C), 128.1, 127.9, 126.4, 124.1 (2C), 121.6. HRMS calcd for C₁₄H₉N₃O₃ [M + H⁺] 268.0717, found 268.0709.

2-(4-(*Trifluoromethoxy*)*phenyl*)*quinazolin-4*(3*H*)-one (**3***ak*).²⁹ White solid; Yield: 78% (119 mg); mp 267–271 °C (lit. 268–271 °C); IR (KBr) cm⁻¹: 3401, 2922, 1654, 1403, 1218, 1156, 1069; ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.62 (br.s, 1H), 8.32 (d, *J* = 7.76 Hz, 1H), 7.86–7.83 (t, *J* = 7.26 Hz, 1H), 7.76 (d, *J* = 7.97 Hz, 1H), 7.55–7.54 (m, 4H); ¹³C NMR (100 MHz, DMSO-*d*₆): δ 162.6, 151.6, 150.8 (d, *J*_{C-F} = 1.22 Hz), 149.0, 135.1, 132.3, 130.5 (2C), 128.0, 127.2, 126.3, 124.3, 121.7, 121.4, 121.3 (2C), 119.1 (q, *J*_{C-F} = 256.6 Hz), 116.6; HRMS calcd for C₁₅H₉F₃N₂O₂ [M + H⁺] 307.0689, found 307.0678.

2-(4-(*Trifluoromethyl*)*phenyl*)*quinazolin-4*(*3H*)-*one* (*3al*).²⁹ White solid; Yield: 81% (117 mg); mp > 300 °C (lit. 308–310 °C); IR (KBr) cm⁻¹: 3400, 3019, 1653, 1403, 1216, 1155, 1067, 669; ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.72 (s, 1H), 8.40 (d, *J* = 8.03 Hz, 2H), 8.18 (d, *J* = 7.79 Hz, 1H), 7.91 (d, *J* = 8.23 Hz, 2H), 7.87–7.83 (t, *J* = 8.03 Hz, 1H), 7.78 (d, *J* = 7.93 Hz, 1H), 7.56–7.53 (t, *J* = 7.50 Hz, 1H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 162.6, 151.6, 148.8, 137.1, 135.1 (2C), 131.5 (q, *J*_{C-F} = 31.33 Hz), 129.1, 128.4, 128.0, 127.4, 126.3, 125.9 (d, *J*_{C-F} = 3.43 Hz), 125.7, 123.0 (q, *J*_{C-F} = 272.7), 121.6; HRMS calcd for C₁₅H₁₀F₃N₂O [M + H⁺] 291.0740, found 291.0742.

2-(*Naphthalen-1-yl)quinazolin-4(3H)-one* (**3am**).¹⁰ White solid; Yield: 75% (102 mg); mp 297–299 °C (lit. 298–300 °C); IR (KBr) cm⁻¹: 3019, 2400, 1675, 1403, 1385, 1069; ¹H NMR (400 MHz, DMSO- d_6): δ 12.66 (br.s, 1H), 8.23 (d, J = 7.84 Hz, 1H), 8.19 (d, J = 7.64 Hz, 1H), 8.13 (d, J = 8.23 Hz, 1H), 8.06 (d, J = 7.25 Hz, 1H), 7.88–7.85 (t, J = 7.05 Hz, 1H), 7.81 (d, J = 6.86 Hz, 1H), 7.74 (d, J = 7.84 Hz, 1H), 7.67–7.56 (m, 4H); ¹³C NMR (100 MHz, DMSO- d_6): δ 162.5, 154.2, 149.1, 134.9, 133.6, 132.2, 130.8, 130.7, 128.8, 128.1, 127.8, 127.5, 127.2, 126.8, 126.3, 125.6, 125.5, 121.6. HRMS calcd for C₁₈H₁₂N₂O [M + H⁺] 273.1022, found 273.1025.

2-(*Pyridin*-3-*yl*)*quinazolin*-4(3*H*)-one (**3***an*).¹⁰ White solid; Yield: 65% (72 mg); mp 280–282 °C (lit. 278–281 °C); IR (KBr) cm⁻¹: 3400, 3019, 2926, 1677, 1402, 1215, 1108; ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.72 (s, 1H), 9.30 (s, 1H), 8.76 (d, J = 4.08 Hz, 1H), 8.51–8.48 (m, 1H), 8.18–8.16 (dd, $J_1 = 7.93$ Hz, $J_2 = 1.08$ Hz, 1H), 7.88–7.84 (m, 1H), 7.78–7.76 (dd, $J_1 = 8.14$ Hz, $J_2 = 0.57$ Hz, 1H), 7.60–7.53 (m, 2H); ¹³C NMR (100 MHz, DMSO-*d*₆): δ 162.6, 152.2, 151.2, 149.2, 148.9, 135.8, 135.1, 129.2, 127.9, 127.4, 126.3, 124.0, 121.5. HRMS calcd for C₁₃H₉N₃O [M + H⁺] 224.0818, found 224.0811.

2-(Quinolin-4-yl)quinazolin-4(3H)-one (**3ao**). White solid; Yield: 61% (83 mg); mp > 300 °C; IR (KBr) cm⁻¹: 3019, 1644, 1403, 1215, 1069; ¹H NMR (400 MHz, DMSO- d_6): δ 12.83 (br.s, 1H), 9.09 (d, J = 3.73 Hz, 1H), 8.25–8.22 (m, 2H), 8.17 (d, J = 8.59 Hz, 1H), 7.92– 7.84 (m, 2H), 7.81 (d, J = 4.29 Hz, 1H), 7.78 (d, J = 8.03 Hz, 1H), 7.70–7.66 (t, J = 7.65 Hz, 1H), 7.64–7.61 (t, J = 7.47 Hz, 1H); ¹³C NMR (100 MHz, DMSO- d_6): δ 162.1, 152.1, 150.5, 148.8, 148.4, 139.6, 135.1 (2C), 133.1, 130.3, 129.9, 128.0 (2C), 127.7, 126.3, 126.0, 122.0. HRMS calcd for C₁₇H₁₁N₃O [M + H⁺] 274.0975, found 274.0975.

2-(*Furan-2-yl*)*quinazolin-4(3H*)-one (**3ap**).¹⁰ White solid.; Yield: 78% (82 mg); mp 275–276 °C (lit. 274–276 °C); IR (KBr) cm⁻¹: 3407, 1660, 1401, 1218, 1069; ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.49 (s, 1H), 8.13 (d, *J* = 7.51 Hz, 1H), 7.99 (s, 1H), 7.82–7.78 (t, *J* = 7.28 Hz, 1H), 7.69 (d, *J* = 8.01 Hz, 1H), 7.63 (d, *J* = 3.37 Hz, 1H), 7.50–7.46 (t, *J* = 7.64 Hz, 1H), 6.75–6.74 (m, 1H); ¹³C NMR (100 MHz, DMSO-*d*₆): δ 162.1, 149.0, 147.0, 146.5, 144.5, 135.0, 127.6, 126.9, 121.5, 114.9, 112.9. HRMS calcd for C₁₂H₈N₂O₂ [M + H⁺] 213.0659, found 213.0656.

2-(Thiophene-2-yl)quinazolin-4(3H)-one (**3aq**).¹⁰ White solid; Yield: 81% (92 mg); mp 221–222 °C (lit. 220–221 °C); IR (KBr) cm⁻¹: 3403, 3019, 1664, 1403, 1215, 1069; ¹H NMR (400 MHz, DMSO- d_6): δ 12.65 (br.s 1H), 8.24–8.23 (dd, J_1 = 3.77, J_2 = 0.87 Hz, 1H), 8.14–8.12 (dd, J_1 = 7.91 Hz, J_2 = 1.17 Hz, 1H), 7.88–7.86 (dd, J_1 = 5.02 Hz, J_2 = 0.91 Hz, 1H), 7.83–7.79 (m, 1H), 7.67 (d, J = 7.96 Hz, 1H), 7.51–7.47 (m, 1H), 7.25–7.23 (m, 1H); ¹³C NMR (100 MHz, DMSO- d_6 + CDCl₃): δ 162.2, 149.1, 148.3, 137.8, 135.1, 132.6, 129.8, 128.9, 127.4, 126.7, 126.4, 121.3. HRMS calcd for C₁₂H₈N₂OS [M + H⁺] 229.0430, found 229.0441.

*(E)-2-Styrylquinazolin-4(3H)-one (3ar).*⁹ Light yellow solid; Yield: 71% (88 mg); mp 226–228 °C (lit. 226–228 °C); IR (KBr) cm⁻¹: 3019, 2399, 1669, 1403, 1385, 1215, 1109; ¹H NMR (400 MHz, DMSO- d_6): δ 12.34 (br.s, 1H), 8.12 (d, J = 7.24 Hz, 1H), 7.97 (d, J = 16.25 Hz, 1H), 7.82–7.78 (m, 1H), 7.69–7.66 (m, 3H), 7.49–7.39 (m, 4H), 7.05 (d, J = 16.25 Hz, 1H); ¹³C NMR (100 MHz, DMSO- d_6): δ 162.5, 152.2, 149.5, 138.5, 135.5, 134.8, 130.1, 129.5 (2C), 128.0 (2C), 127.4, 126.5, 126.3, 121.8, 121.5. HRMS calcd for C₁₆H₁₂N₂O [M + H⁺] 249.1022, found 249.1034.

2-*Ethylquinazolin-4(3H)-one* (**3***a***s**).¹² White solid; Yield: 42% (36 mg); mp 228–230 °C (lit. 229–231 °C); IR (KBr) cm⁻¹: 3399, 3019, 2400, 1672, 1618, 1469, 1403, 1385, 1070; ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.14 (s, 1H), 8.08 (d, *J* = 7.63 Hz, 1H), 7.77–7.73 (t, *J* = 7.32 Hz, 1H), 7.60 (d, *J* = 8.02 Hz, 1H), 7.46–7.42 (t, *J* = 7.32 Hz, 1H), 2.64–2.59 (quart, *J* = 7.40 Hz, 2H), 1.26–1.22 (t, *J* = 7.40 Hz, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆): δ 162.2, 158.7, 149.4, 134.6, 127.2, 126.3, 126.1, 121.2, 28.2, 11.7. HRMS calcd for C₁₀H₁₀N₂O [M + H⁺] 175.0866, found 175.0858.

2-Pentylquinazolin-4(3H)-one (**3at**).²⁷ White solid; Yield: 49% (52 mg); mp 152–154 °C (lit. 153–154 °C); IR (KBr) cm⁻¹: 3019, 1674, 1468, 1215, 929; ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.15 (s, 1H), 8.08 (d, *J* = 7.20 Hz, 1H), 7.78–7.74 (t, *J* = 8.03 Hz, 1H), 7.60 (d, *J* = 8.13 Hz, 1H), 7.46–7.42 (t, *J* = 7.54 Hz, 1H), 2.60–2.56 (t, *J* = 7.44 Hz, 2H), 1.73–1.70 (m, 2H), 1.32–1.28 (m, 4H), 0.88–0.84 (t, *J* = 6.46 Hz, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆): δ 162.2, 157.9, 149.4, 134.7, 127.2, 126.3, 126.1, 121.2, 34.9, 31.2, 26.9, 22.2, 14.2. HRMS calcd for C₁₃H₁₆N₂O [M + H⁺] 217.1335, found 217.1327. 2-Benzylquinazolin-4(3H)-one (**3au**).¹⁷ White solid; Yield: 57%

2-Benzylquinazolin-4(3H)-one (3au).¹⁷ White solid; Yield: 57% (67 mg); mp 248–250 °C (lit. 245–247 °C); IR (KBr) cm⁻¹: 3401, 3019, 1619, 1403, 1215, 1069; ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.37 (br.s, 1H), 8.09–8.07 (d, *J* = 7.66 Hz, 1H), 7.79–7.75 (t, *J* = 7.46 Hz, 1H), 7.62 (d, *J* = 8.04 Hz, 1H), 7.48–7.45 (t, *J* = 7.46 Hz, 1H), 7.40 (d, *J* = 7.18 Hz, 2H), 7.34–7.30 (t, *J* = 7.27 Hz, 2H), 7.26–7.22 (t, *J* = 7.08 Hz, 1H), 3.94 (s, 2H); ¹³C NMR (100 MHz, DMSO-*d*₆): δ 162.4, 156.5, 149.3, 137.0, 134.8, 129.3 (2C), 128.9 (2C), 127.2 (2C), 126.6, 126.1, 121.1, 41.2; HRMS calcd for C₁₅H₁₂N₂O [M + H⁺] 237.1022, found 237.1001.

Quinazolin-4(3H)-one (**3av**).²⁵ White solid; Yield: 41% (30 mg); mp 211–214 °C (lit. 212–214 °C); IR (KBr) cm⁻¹: 3401, 3019, 1667, 1403, 1067; ¹H NMR (400 MHz, DMSO- d_6): δ 12.22 (s, 1H), 8.13–8.10 (dd, J_1 = 7.93 Hz, J_2 = 1.22 Hz, 1H), 8.08 (s, 1H), 7.82–7.78 (m, 1H), 7.62 (d, J = 7.84 Hz, 1H), 7.53–7.49 (m, 1H); ¹³C NMR (100 MHz, DMSO- d_6): δ 161.2, 149.1, 145.8, 134.7, 127.6, 127.1, 126.2, 123.1. HRMS calcd for C₈H₆N₂O [M + H⁺] 147.0553, found 147.0543.

7-Methyl-2-phenylquinazolin-4(3H)-one (**3ba**).¹⁰ White solid; Yield: 82% (96 mg); mp 238–240 °C (lit. 240–241 °C); IR (KBr) cm⁻¹: 3019, 1666, 1605, 1402, 1069; ¹H NMR (400 MHz, DMSO- d_6): δ 12.44 (s, 1H), 8.18 (d, *J* = 6.85 Hz, 2H), 8.05 (d, *J* = 8.05 Hz, 1H), 7.61–7.53 (m, 4H), 7.36 (d, *J* = 8.23 Hz, 1H), 2.48 (s, 3H); ¹³C NMR (100 MHz, DMSO- d_6): δ 162.2, 152.7, 149.3, 145.5, 133.2, 131.7, 129.0 (2C), 128.4, 128.1 (2C), 127.6, 126.1, 119.0, 21.8. HRMS calcd for C₁₅H₁₂N₂O [M + H⁺] 237.1022, found 237.1012.

7-Methyl-2-(4-Methoxyphenyl)quinazolin-4(3H)-one (**3bb**).¹⁰ Light yellow solid; Yield: 84% (111 mg); mp 248–250 °C (lit. 246–248 °C); IR (KBr) cm⁻¹: 3403, 3019, 1663, 1403, 1069; ¹H NMR (400 MHz, DMSO- d_6): δ 12.32 (br.s, 1H), 8.19 (d, *J* = 8.69 Hz, 2H), 8.03 (d, *J* = 8.11 Hz, 1H), 7.52 (s, 1H), 7.32 (d, *J* = 8.11 Hz, 1H), 7.10 (d, *J* = 8.69 Hz, 2H), 3.85 (s, 3H), 2.47 (s, 3H); ¹³C NMR (100 MHz, DMSO- d_6): δ 162.6, 162.3, 152.3, 149.5, 149.4, 129.8 (2C), 128.0, 127.4, 126.1, 125.3, 118.7, 114.4 (2C), 55.9, 21.8. HRMS calcd for C₁₆H₁₄N₂O₂ [M + H⁺] 267.1128, found 267.1125.

7-Methyl-2-(pyridin-3-yl)quinazolin-4(3H)-one (**3bn**). White solid; Yield: 62% (73 mg); mp 256–260 °C; IR (KBr) cm⁻¹: 3681, 3400, 3019, 2399, 1669, 1605, 1522, 1474, 1419, 1024, 669, 626; ¹H NMR (400 MHz, DMSO- d_6): δ 12.95 (br.s, 1H), 9.29 (s, 1H), 8.75 (s, 1H), 8.49 (d, J = 7.72 Hz, 1H), 8.06 (d, J = 8.05 Hz, 1H), 7.59–7.57 (m, 2H), 7.37 (d, J = 7.89 Hz, 1H), 2.48 (s, 3H); ¹³C NMR (100 MHz, DMSO- d_6): δ 162.5, 152.2, 151.2, 149.1, 145.6, 135.7 (2C), 128.8, 127.6, 126.2, 124.0, 119.1, 21.8. HRMS calcd for C₁₄H₁₁N₃O [M + H⁺] 238.0975, found 238.0970.

7-*Methyl-2-(thiophen-2-yl)quinazolin-4(3H)-one* (**3bq**).¹⁰ White solid; Yield: 80% (96 mg); mp 290–293 °C (lit. 291–292 °C); IR (KBr) cm⁻¹: 3401, 3018, 1660, 1403, 1215, 1069; ¹H NMR (400 MHz, DMSO- d_6): δ 12.55 (s, 1H), 8.22 (d, *J* = 3.33 Hz, 1H), 8.01 (d, *J* = 8.05 Hz, 1H), 7.86 (d. *J* = 4.90 Hz, 1H), 7.48 (s, 1H), 7.32 (d, *J* = 8.00 Hz, 1H), 7.24–7.22 (t, *J* = 4.24 Hz, 1H), 2.45 (s, 3H); ¹³C NMR (100 MHz, DMSO- d_6): δ 162.1, 149.2, 148.3, 145.6, 137.9, 132.5, 129.7, 128.9, 128.2, 127.1, 126.2, 118.9, 21.7. HRMS calcd for C₁₃H₁₀N₂OS [M + H⁺] 243.0587, found 243.0581.

7-Methyl-2-pentylquinazolin-4(3H)-one (*3bt*). White solid; Yield: 44% (50 mg); mp. 180–182 °C; IR (KBr) cm⁻¹: 3394, 2925, 1675, 1616, 1403, 1217, 1068, 670; ¹H NMR (400 MHz, CDCl₃): δ 10.92 (s, 1H), 8.16 (d, *J* = 8.05 Hz, 1H), 7.49 (s, 1H), 7.29 (d, *J* = 8.37 Hz, 2H), 2.76–2.72 (t, *J* = 7.72 Hz, 2H), 2.50 (s, 3H), 1.89–1.82 (m, 2H), 1.46–1.35 (m, 4H), 0.93–0.90 (t, *J* = 6.91 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 163.5, 156.6, 149.4, 145.8, 127.9, 126.9, 126.0, 118.1, 35.9, 31.3, 27.1, 22.3, 21.9, 13.9. HRMS calcd for C₁₄H₁₈N₂O [M + H⁺] 231.1492, found 231.1495.

6-Methoxy-2-phenylquinazolin-4(3H)-one (3ca).¹⁰ Light yellow solid; Yield: 82% (103 mg); mp 246–247 °C (lit. 249–251 °C); IR (KBr) cm⁻¹: 3400, 3019, 1664, 1403, 1069; ¹H NMR (400 MHz, DMSO- d_6): δ 12.49 (s, 1H), 8.17 (d, *J* = 6.66 Hz, 2H), 7.71 (d, *J* = 8.76 Hz, 1H), 7.55–7.53 (m, 4H), 7.46–7.43 (dd, *J*₁ = 8.81 Hz, *J*₂ = 2.71 Hz, 1H), 3.90 (s, 3H); ¹³C NMR (100 MHz, DMSO- d_6): δ 162.5, 158.2, 150.5, 143.6, 133.2, 131.4, 129.6, 129.0 (2C), 127.9 (2C), 124.5, 122.2, 106.3, 56.1. HRMS calcd for C₁₅H₁₂N₂O₂ [M + H⁺] 253.0972, found 253.0975.

6-Methoxy-2-(4-methoxy)phenyl)quinazolin-4(3H)-one (**3cb**).²⁸ Light yellow solid; Yield: 80% (112 mg); mp 256–258 °C (lit. 258–259 °C); IR (KBr) cm⁻¹: 3397, 1629, 1401, 1068, 770; ¹H NMR (400 MHz, DMSO- d_6): δ 12.37 (s, 1H), 8.17 (d, *J* = 8.28 Hz, 2H), 7.67 (d, *J* = 8.76 Hz, 1H), 7.53 (s, 1H), 7.43 (d, *J* = 7.05 Hz, 1H), 7.09 (d, *J* = 8.24 Hz, 2H), 3.89 (s, 3H), 3.84 (s, 3H); ¹³C NMR (100 MHz, DMSO- d_6): δ 162.1, 161.5, 157.4, 149.7, 143.4, 129.1 (2C), 129.0, 124.9, 124.0, 121.4, 113.9 (2C), 105.8, 55.6, 55.4. HRMS calcd for C₁₆H₁₄N₂O₃ [M + H⁺] requires 283.1077, found 283.1078. 2-Propylquinazolin-4(3H)-one (**5a**).¹² White solid; Yield: 45% (42

2-Propylquinazolin-4(3H)-one (**5a**l).¹² White solid; Yield: 45% (42 mg); mp 198–200 °C (lit. 200–202 °C); IR (KBr) cm⁻¹: 3400, 3019, 2400, 1671, 1612, 1466, 1403, 1385, 1069; ¹H NMR (400 MHz, CDCl₃): δ 11.47 (br.s, 1H), 8.30–8.27 (dd, J_1 = 7.97 Hz, J_2 = 1.08 Hz, 1H), 7.79–7.75 (m, 1H), 2.79–2.75 (t, J = 7.66 Hz, 2H), 1.97–1.87 (sxt, J = 7.46 Hz, 2H), 1.10–1.06 (t, J = 7.37 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 164.1, 156.7, 149.6, 135.0, 130.3, 128.6, 127.4, 126.6, 126.4, 120.7, 37.9, 21.1, 13.9. HRMS calcd for C₁₁H₁₂N₂O [M + H⁺] 189.1022, found 189.1024.

2-Heptylquinazolin-4(3H)-one (5am).²⁷ White solid; Yield: 48% (58 mg); mp 123–126 °C (lit. 124–127 °C); IR (KBr) cm⁻¹: 2924, 1673, 1612, 1468, 1149; ¹H NMR (400 MHz, CDCl₃): δ 11.30 (s, 1H), 8.29–8.27 (dd, J_1 = 8.01 Hz, J_2 = 1.07 Hz, 1H), 7.79–7.75 (m, 1H), 7.71–7.69 (dd, J_1 = 8.15 Hz, J_2 = 0.58 Hz, 1H), 7.48–7.44 (m, 1H), 2.79–2.75 (t, J = 7.80 Hz, 2H), 1.91–1.83 (m, 2H), 1.49–1.42 (m, 2H), 1.41–1.34 (m, 2H), 1.30–1.25 (m, 4H), 0.89–0.85 (t, J = 6.86 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 63.8, 156.7, 149.4, 134.7, 127.2, 126.3, 126.2, 120.5, 36.0, 31.6, 29.1, 28.9, 27.5, 22.5, 14.0. HRMS calcd for C₁₅H₂₀N₂O [M + H⁺] 245.1648, found 245.1644.

2-(3,5-Dimethylphenyl)quinazolin-4(3H)-one (7ac).²⁴ White solid; Yield: 44% (55 mg); mp 271–273 °C (lit. 273 °C); IR (KBr) cm⁻¹: 3402, 3021, 2401, 1665, 1523, 1417, 1027, 928, 670; ¹H NMR (400 MHz, DMSO- d_6): δ 12.38 (s, 1H), 8.15–8.14 (d, J = 7.54 Hz, 1H), 7.85–7.81 (m, 3H), 7.75–7.73 (d, J = 8.17 Hz, 1H), 7.53–7.49 (t, J = 7.34 Hz, 1H), 7.22 (s, 1H), 2.37 (s, 6H); ¹³C NMR (100 MHz, DMSO- d_6): δ 162.6, 152.9, 149.2, 138.2, 135.0, 133.2, 133.0, 127.9, 126.9, 126.3, 125.9, 121.4, 21.3 (2C). HRMS calcd for $C_{16}H_{14}N_2O\ [M + H^+]\ 251.1179,$ found 251.1178.

2-(o-Tolyl)quinazolin-4(3H)-one (**7ae**).²⁰ White solid; Yield: 67% (79 mg); mp 215–218 °C (lit. 216–218 °C); IR (KBr) cm⁻¹: 3391, 3019, 2400, 1612, 1403, 1068, 669; ¹H NMR (400 MHz, DMSO- d_6): δ 12.43 (s, 1H), 8.18 (d, J = 7.42 Hz, 1H), 7.85–7.82 (t, J = 6.98 Hz, 1H), 7.70 (d, J = 8.05 Hz, 1H), 7.56–7.50 (m, 2H), 7.45–7.42 (t, J = 6.98 Hz, 1H), 7.36–7.31 (m, 2H), 2.39 (s, 3H); ¹³C NMR (100 MHz, DMSO- d_6): δ 162.2, 154.8, 149.2, 136.5, 134.9, 134.7, 130.9, 130.3, 129.5, 127.8, 127.0, 126.2, 126.1, 121.4, 20.0. HRMS calcd for C₁₅H₁₂N₂O [M + H⁺] 237.1022, found 237.1018.

2-(*p*-Tolyl)quinazolin-4(3*H*)-one (**7af**).²⁰ White solid; Yield: 65% (76 mg); mp 241–243 °C (lit. 239–242 °C); IR (KBr) cm⁻¹:3401, 3019, 2400, 1663, 1403, 1156, 1069; ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.44 (s, 1H), 8.15 (d, *J* = 7.44 Hz, 1H), 8.10 (d, *J* = 8.13 Hz, 2H), 7.83–7.79 (t, 1H, *J* = 7.05 Hz), 7.72 (d, *J* = 7.84 Hz, 1H), 7.51–7.47 (t, *J* = 7.44 Hz, 1H), 7.35 (d, *J* = 7.93 Hz. 2H), 2.38 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆): δ 162.7, 152.6, 149.2, 141.8, 134.9, 130.3, 129.6, 128.1, 127.8, 126.8, 126.2, 21.4. HRMS calcd for C₁₅H₁₂N₂O [M + H⁺] 237.1022, found 237.1016.

2-(m-Tolyl)quinazolin-4(3H)-one (**7ag**).²⁰ White solid; Yield: 59% (69 mg); mp 220–222 °C (lit. 221–223 °C); IR (KBr) cm⁻¹: 3407, 3019, 1674, 1403, 1216, 1069; ¹H NMR (400 MHz, DMSO- d_6): δ 12.46 (br.s, 1H), 8.17–8.15 (m, 1H), 8.03 (s, 1H), 7.98 (d, J = 7.24 Hz, 1H), 7.86–7.82 (m, 1H), 7.76 (d, J = 7.89 Hz, 1H), 7.54–7.50 (m, 1H), 7.46–7.39 (m, 2H), 2.41 (s, 3H); ¹³C NMR (100 MHz; DMSO- d_6): δ 162.6, 152.8, 149.2, 138.3, 135.0, 133.1, 132.4, 128.9, 128.7, 127.9, 126.9, 126.3, 125.3, 121.4, 21.4. HRMS calcd for C₁₅H₁₂N₂O [M + H⁺] 237.1022, found 237.1009. 2-Aminobenzamide (**8**).⁹ To a mixture of 2-bromobenzamide 1a

(0.30 g, 1.5 mmol) and CuI (0.03 g, 0.15 mmol) in DMSO (3.0 mL) was added TMSN₃ (0.39 mL, 3.0 mmol) in a tube under an air atmosphere. After that, the tube was sealed, and the reaction mixture was heated at 80 °C for 24 h. After completion of the reaction, water (20 mL) was added to it. A saturated aq. Na₂S₂O₃ solution was added until the disappearance of brown color, and the reaction mixture was extracted with ethyl acetate. The combined organic layer was dried on anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the crude product was purified by column (SiO₂, 60-120) chromatography using 20-25% EtOAc:hexane as eluent to get pure 2-aminobenzamide products. White solid; Yield: 4% (8 mg); mp 110-112 °C (lit. 110 °C); IR (KBr) cm⁻¹: 3409, 3020, 2401, 1659, 1590, 1399, 1316, 1075; ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.71 (br.s, 1H), 7.54 (d, J = 7.84 Hz, 1H), 7.15-7.11 (t, J = 8.00 Hz, 1H), 7.04 (br.s, 1H), 6.69 (d, J = 8.17 Hz, 1H), 6.55 (br.s, 1H), 6.50–6.46 (t, J = 7.15 Hz, 1H); ¹³C NMR (100 MHz, DMSO-*d*₆): δ 171.7, 150.6, 132.3, 129.2, 116.8, 114.8, 114.1. HRMS calcd for C₇H₈N₂O [M + H⁺] 137.0709, found 137.0713

2-Phenyl-2,3-dihydroquinazolin-4(1H)-one (9).9 To a stirred mixture of 2-bromobenzamide 1a (0.10 g, 0.5 mmol), benzaldehyde (0.06 mL, 0.6 mmol), and CuI (0.01 g, 0.05 mmol) in DMSO (1.5 mL) was added TMSN₃ (0.13 mL, 1.0 mmol) in a tube under a nitrogen atmosphere. After that, the tube was sealed, and the reaction mixture was heated at 80 °C for 24 h. After completion of the reaction, water (20 mL) was added to it. A saturated aq. Na₂S₂O₃ solution was added until the disappearance of brown color, and the reaction mixture was extracted with ethyl acetate. The combined organic layer was dried on anhydrous sodium sulfate. The combined organic layer was dried on anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the crude product was purified by column (SiO₂, 60-120) chromatography using 15-20% EtOAc:hexane as eluent to get the pure dihydroquinazolinone product. White solid; Yield: 87% (0.19 g); mp 221-222 °C (lit. 220-223 °C); IR (KBr) cm⁻¹: 3297, 3019, 1659; ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.27 (br.s, 1H), 7.62-7.60 (m, 1H), 7.51-7.49 (m, 2H), 7.41-7.33 (m, 3H), 7.26-7.22 (m, 1H), 7.10 (br.s, 1H), 6.76 (d, J = 8.01 Hz, 1H), 6.69-6.66 (t, J = 7.44 Hz, 1H), 5.75 (s, 1H); ¹³C NMR (100 MHz, DMSO-d₆): δ 164.0, 8.3, 142.1, 133.7, 128.9, 128.7 (2C), 127.8, 127.3 (2C), 117.5, 115.4, 114.8, 67.0. HRMS calcd for C₁₄H₁₂N₂O [M + H⁺] 225.1022, found 225.1013.

The Journal of Organic Chemistry

2-(Benzylamino)benzamide (11).¹⁰ To a stirred mixture of 2aminobenzamide (8; 1.0 g, 7.4 mmol), K₂CO₃ (1.0 g, 7.4 mmol), and NaI (1.1 g, 7.4 mmol) in DMF (10 mL) was added benzyl chloride (1.2 mL, 10 mmol), and the mixture was stirred at rt for 1 day. The reaction mixture was cooled and poured into water. It was extracted with EtOAc. The organic layer was washed with brine, dried over MgSO₄, and concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, hexanes/EtOAc) to give desired product 11 (1.5 g, 90%) as a pale yellow solid: mp 170-172 °C (lit. 176-177 °C); IR (KBr) (cm-1) 3423, 3205, 1634, 1578, 1512, 1393, 1292, 1066, 747; ¹H NMR (400 MHz, DMSO- d_6): δ 8.60–8.57 (t, J = 5.39 Hz, 1H), 7.85 (br.s, 1H), 7.63-7.61 (m, 1H), 7.34-7.33 (m, 4H), 7.26-7.18 (m, 3H), 6.63 (d, J = 8.49 Hz, 1H), 6.55-6.51 (t, J = 7.67 Hz, 1H), 4.39 (d, J = 5.71 Hz, 1H); ¹³C NMR (100 MHz, DMSO-d₆): δ 172.0, 150.0, 140.1, 132.9, 129.5, 128.9 (2C), 127.5 (2C), 127.2, 114.6, 111.9, 46.4. HRMS calcd for C₁₄H₁₄N₂O [M + H⁺] 227.1179, found 227.1166.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.6b00599.

Copies of ¹H and ¹³C NMR spectra (PDF)

AUTHOR INFORMATION

Corresponding Author

*E-mail: rpt.cdri@gmail.com, rp_tripathi@cdri.res.in. Tel: +91 522 2612411. Fax: +91 522 2623405.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

K.U. and R.K.T. would like to thank UGC, New Delhi, for providing a fellowship. We thank SAIF division, CSIR-CDRI, for the analytical facilities. Financial support of Indo French collaborative CEFIPRA project 5303-2 is greatly acknowledged. It is a CDRI communication no. 9239.

REFERENCES

(1) Mhaske, S. B.; Argade, N. P. Tetrahedron 2006, 62, 9787.

(2) (a) Takase, Y.; Saeki, T.; Watanabe, N.; Adachi, H.; Souda, S.; Saito, I. J. Med. Chem. **1994**, 37, 2106–2111. (b) Dupuy, M.; Pinguet, F.; Chavignon, O.; Chezal, J. M.; Teulade, J. C.; Chapat, J. P.; Blache, Y. Chem. Pharm. Bull. **2001**, 49, 1061. (c) Chandrika, P. M.; Yakaiah, T.; Rao, A. R. R.; Narsaiah, B.; Reddy, N. C.; Sridhar, V.; Rao, J. V. Eur. J. Med. Chem. **2008**, 43, 846.

(3) Kikuchi, H.; Yamamoto, K.; Horoiwa, S.; Hirai, S.; Kasahara, R.; Hariguchi, N.; Matsumoto, M.; Oshima, Y. J. Med. Chem. 2006, 49, 4698.

(4) Yen, M.-H.; Sheu, J.-R.; Peng, I.-H.; Lee, Y.-M.; Chern, J.-W. J. J. Pharm. Pharmacol. **1996**, 48, 90.

(5) (a) Alagarsamy, V.; Solomon, V. R.; Dhanabal, K. *Bioorg. Med. Chem.* **2007**, *15*, 235. (b) Baba, A.; Kawamura, N.; Makino, H.; Ohta, Y.; Taketomi, S.; Sohda, T. J. Med. Chem. **1996**, *39*, 5176.

(6) Nandy, P.; Vishalakshi, M. T.; Bhat, A. R. Indian J. Heterocycl. Chem. 2006, 15, 293.

(7) (a) Connolly, D. J.; Cusack, D.; O'Sullivan, T. P.; Guiry, P. J. *Tetrahedron* **2005**, *61*, 10153. (b) He, L.; Li, H.; Chen, J.; Wu, X.-F. RSC Adv. **2014**, *4*, 12065.

(8) (a) Mitobe, Y.; Ito, S.; Mizutani, T.; Nagase, T.; Sato, N.; Tokita, S. Bioorg. Med. Chem. Lett. 2009, 19, 4075. (b) Balakumar, C.; Lamba, P.; Kishore, D. P.; Narayana, B. L.; Rao, K. V.; Rajwinder, K.; Rao, A. R.; Shireesha, B.; Narsaiah, B. Eur. J. Med. Chem. 2010, 45, 4904. (c) Zhan, D.; Li, T.; Wei, H.; Weng, W.; Ghandi, K.; Zeng, Q. RSC Adv. 2013, 3, 9325. (d) Ge, W.; Zhu, X.; Wei, Y. RSC Adv. 2013, 3, 10817. (e) Kim, N. Y.; Cheon, C.-H. Tetrahedron Lett. 2014, 55, 2340.

- (9) Guo, S.; Li, Y.; Tao, L.; Zhang, W.; Fan, X. RSC Adv. 2014, 4, 59289.
- (10) Xu, W.; Jin, Y.; Liu, H.; Jiang, Y.; Fu, H. Org. Lett. 2011, 13, 1274.
- (11) Huang, C.; Fu, Y.; Fu, H.; Jiang, Y.; Zhao, Y. Chem. Commun. 2008, 6333.
- (12) Xu, W.; Fu, H. J. Org. Chem. 2011, 76, 3846.
- (13) Xu, L.; Jiang, Y.; Ma, D. Org. Lett. 2012, 14, 1150.
- (14) Wu, X.-F.; He, L.; Neumann, H.; Beller, M. Chem.—Eur. J. 2013, 19, 12635.
- (15) Mohammed, S.; Vishwakarma, R. A.; Bharate, S. B. J. Org. Chem. 2015, 80, 6915.

(16) Yang, X.; Cheng, G.; Shen, J.; Kuai, C.; Cui, X. Org. Chem. Front. 2015, 2, 366.

(17) Zhou, J.; Fang, J. J. Org. Chem. 2011, 76, 7730.

(18) Siddiki, S. M. A. H.; Kon, K.; Touchy, A. S.; Shimizu, K.-i. Catal. Sci. Technol. 2014, 4, 1716.

(19) Hikawa, H.; Ino, Y.; Suzuki, H.; Yokoyama, Y. J. Org. Chem. 2012, 77, 7046.

(20) Zhao, D.; Wang, T.; Li, J.-X. Chem. Commun. 2014, 50, 6471.
(21) (a) Monguchi, Y.; Maejima, T.; Mori, S.; Maegawa, T.; Sajiki, H. Chem.—Eur. J. 2010, 16, 7372. (b) Maejima, T.; Shimoda, Y.; Nozaki, K.; Mori, S.; Sawama, Y.; Monguchi, Y.; Sajiki, H. Tetrahedron 2012, 68, 1712. (c) Maejima, T.; Ueda, M.; Nakano, J.; Sawama, Y.;

Monguchi, Y.; Sajiki, H. J. Org. Chem. 2013, 78, 8980. (22) (a) Maejima, T.; Ueda, M.; Nakano, J.; Sawama, Y.; Monguchi,

Y.; Sajiki, H. J. Org. Chem. 2013, 78, 8980. (b) Xia, Q.; Chen, W. J. Org. Chem. 2012, 77, 9366. (c) Boess, E.; Schmitz, C.; Klussmann, M. J. Am. Chem. Soc. 2012, 134, 5317. (d) Studer, A. Chem.—Eur. J. 2001, 7, 1159. (e) Minisci, F.; Recupero, F.; Cecchetto, A.; Gambarotti, C.; Punta, C.; Faletti, R.; Paganelli, R.; Pedulli, G. F. Eur. J. Org. Chem. 2004, 2004, 109. (f) Bravo, A.; Bjorsvik, H. R.; Fontana, F.; Liguori, L.; Minisci, F. J. Org. Chem. 1997, 62, 3849.

(23) Hour, M.-J.; Huang, L.-J.; Kuo, S.-C.; Xia, Y.; Bastow, K.; Nakanishi, Y.; Hamel, E.; Lee, K.-H. J. Med. Chem. 2000, 43, 4479.

(24) Jiang, X.; Tang, T.; Wang, J.-M.; Chen, Z.; Zhu, Y.-M.; Ji, S.-J. J. Org. Chem. 2014, 79, 5082.

(25) Rao, R.; Mekala, R.; Raghunadh, A.; Meruva, S. B.; Kumar, S. P.; Kalita, D.; Laxminarayana, E.; Prasad, B.; Pal, M. *RSC Adv.* **2015**, *5*, 61575.

(26) Zhang, J.; Ren, D.; Ma, Y.; Wang, W.; Wu, H. *Tetrahedron* **2014**, 70, 5274.

(27) Reen, F. J.; Clarke, S. L.; Legendre, C.; McSweeney, C. M.; Eccles, K. S.; Lawrence, S. E.; O'Gara, F.; McGlacken, G. P. Org. Biomol. Chem. 2012, 10, 8903.

(28) Wang, L.-X.; Xiang, J.-F.; Tang, Y.-L. Eur. J. Org. Chem. 2014, 2014, 2682.

(29) Li, F.; Lu, L.; Ma, J. Org. Chem. Front. 2015, 2, 1589.